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Abstract
Background: Endothelial progenitor cells (EPC) are of major importance in vascular repair under healthy circumstances.
Vascular injury in need of repair occurs frequently in ANCA-associated vasculitis (AAV). A specialized T cell subset
enhancing EPC function and differentiation has recently been described. These angiogenic T cells (Tang) may have
an important impact on the vascular repair process. Therefore, the aim of our study was to investigate EPC and
Tang in AAV.
Methods: Fifty-three patients suffering from AAV and 29 healthy controls (HC) were enrolled in our study.
Forty-four patients were in remission, nine patients were in active state of disease. Patients were either untreated
or were under monotherapy with low-dose steroids (max. 5 mg/day) at the time of sampling. Circulating EPC and
Tang were determined by flow cytometry (FACS). The functional capacity of EPC was assessed by established cell
culture methods.
Results: Circulating EPC were significantly decreased in AAV as compared to HC. The capacity of EPC to differentiate
and proliferate was differentially impaired in patients as compared to HC. The outgrowth of endothelial colony-forming
cells (ECFC) was severely decreased in patients whereas colony-forming units-endothelial cell (CFU-EC) outgrowth was
unaffected. ECFC and CFU-EC differentiation was strictly T cell-dependent. Patients with a relapsing disease course had
an impaired ECFC outgrowth and expansion of Tang as compared to patients with a stable, nonrelapsing disease.
Conclusions: The differentiation process of EPC is impaired in AAV. This may favor insufficient vascular repair
promoting a relapsing disease course. Finally, these factors may explain a higher cardiovascular morbidity as has
been previously documented in AAV.
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Background
ANCA-associated vasculitis (AAV) is a small vessel vas-
culitis of autoimmune origin [1]. It is characterized by
the presence of autoantibodies directed against either
proteinase 3 (PR3) or myeloperoxidase (MPO) [1]. Treat-
ment with immunosuppressive drugs reduces mortality
significantly but needs to be continued even after remis-
sion has been achieved, and despite treatment, relapses
occur frequently [2]. Persistent activation of clotting and
the immune system – even in remission – indicates a
“smoldering”, ongoing low-grade inflammation resulting
in continuous vascular damage, which may contribute to
the relapsing disease course [1, 3–5]. Accordingly, in-
creased numbers of circulating endothelial cells, reflect-
ing vascular damage, have been detected in patients in
remission [6]. Importantly, AAV patients show increased
cardiovascular morbidity and mortality [7–11].
In a healthy situation, vascular damage is repaired by
so-called endothelial progenitor cells (EPC), which are
mobilized from the bone marrow in situations when vas-
cular injury occurs [12–14]. These EPC can be detected
in the circulation. Furthermore, in vitro culture methods
* Correspondence: jw.cohentervaert@maastrichtuniversity.nl
1Immunology, Maastricht University, PO Box 5800, 6202 AZ Maastricht, The
Netherlands
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wilde et al. Arthritis Research & Therapy  (2016) 18:147 
DOI 10.1186/s13075-016-1044-8
have revealed two different types of EPC. Endothelial
colony-forming cells (ECFC) have been reported as the
“real” progenitor cells replacing damaged endothelial cells
whereas colony-forming units-endothelial cells (CFU-EC)
have a supporting function providing the proper cytokine
environment at the place of repair [14, 15]. Reduced EPC
numbers, reflecting diminished vascular repair, are as-
sociated with cardiovascular morbidity and increased
mortality [16]. Recent data suggests that also so-called
angiogenic T cells (Tang) have a pivotal role in vascular
repair and enhance EPC function [17].
We hypothesize that EPC are impaired in AAV, which is
relevant for the relapsing disease course and the increased
cardiovascular mortality. Therefore, we assessed EPC num-
ber by flow cytometry and function by means of in vitro
culture assays. Furthermore, we investigated the role of an-
giogenic T cells, which are supposed to have a role in EPC
differentiation and function, in our AAV patients.
Methods
Patient cohort
Fifty-three patients (mean age 58 ± 15 years) with diagnosed
ANCA-associated vasculitis (Table 1) and 29 age-matched
healthy volunteers were enrolled (mean age 58 ± 9 years).
Nine patients had active disease at presentation and 44
AAV patients were in remission (Table 1). The diagnosis
was made according to criteria of the American College of
Rheumatology and the Chapel Hill Criteria [18, 19]. Active
disease was defined as the presence of clinical manifesta-
tions of new-onset or recurrent disease activity related to
vasculitis requiring intensified immunosuppressive therapy
[20]. Remission/quiescent disease was defined as absence of
clinical disease activity reflecting a Birmingham Vasculitis
Activity Score of zero [20]. All patients included were either
untreated or treated with a maximum dose of 5 mg steroids
at the time of sampling. Current treatment with azathio-
prine, methotrexate, mycophenolate mofetil, cyclophospha-
mide or rituximab was an exclusion criterion. The cohort
of patients in remission was divided in two groups for fur-
ther analysis: (1) patients in long-term, stable remission (2)
patients with relapsing disease course. Patients with a
relapse-free disease course since the first onset of AAV and
a minimum disease duration of 48 months were defined as
being in stable long-term remission (nonrelapsers). Patients
with a minimum disease duration of 48 months and at least
one relapse within the first 48 months since diagnosis were
defined as relapsers [21]. The study was approved by the
local institutional review board and patients gave informed
consent.
Flow cytometric analysis
Circulating endothelial progenitor cells (cEPC) and T
cells were determined by flow cytometry (FACS). The
following antibodies labeled with fluorescent dye were
used: α-human CD3 (mouse IgG1, HorV450), α-human
CD4 (mouse IgG1, PerCP; ITK/Biolegend, Uithoorn,
The Netherlands), α-human CD28 (mouse IgG1, APC),
α-human CD31 (mouse IgG1, FITC), α-human CD34
(mouse IgG1, PerCP), α-human CD45 (mouse IgG1,
AmCyan), α-human KDR/VEGFR2 (mouse IgG1, PerCP,
R&D Systems, Oxon, United Kingdom), α-human CD133/1
(mouse IgG1, APC, Miltenyi Biotec, Leiden, The
Netherlands). All antibodies except CD4, KDR, and
CD133 were purchased from BD Biosciences, Breda,
The Netherlands. Appropriate isotype controls (BD
Biosciences) were used. In addition, an unstained control
sample tube was included to control for autofluorescence.
Monoclonal antibodies were added to 150 μL of whole
blood followed by an incubation period of 30 min in the
dark at room temperature. After red blood cell lysis, at
least 100,000 events were acquired in the lymphocyte gate
by FACS. Sample carryover was minimized by automatic
rinsing of the acquisition needle after each sample tube.
Furthermore, a minimum of 100,000 lymphocytes were
Table 1 Patients’ characteristics and demographics.
AAV patients (n = 53)














Mean CRP 6.5 ± 5.1 mg/L
Active 9 pts
Mean CRP 79 ± 139 mg/L
Mean BVAS 9 ± 6










AAV ANCA-associated vasculitis, BVAS Birmingham Vasculitis Activity Score, CRP
C-reactive protein, MPO myeloperoxidase, PR3 proteinase 3
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acquired per sample tube to ensure accuracy of the meas-
urement. The protocol was adopted and modified after
Duda et al. [22]. Analysis was performed with a FACS
CANTO™ from BD Biosciences.
Data was analyzed using FACS DIVA software (BD
Biosciences). Angiogenic T cells were defined as CD3
+CD31+ according to the definition by Hur et al [17].
cEPC were defined as CD45dim/CD34+/KDR+ cells [23].
Absolute cell counts were calculated from complete blood
counts.
Determination of soluble interleukin-2 receptor and
neopterin plasma levels
Soluble interleukin-2 receptor (sIL-2r) and neopterin levels
were determined in plasma samples by commercially avail-
able ELISA kits (sIL-2r: Diaclone Research, Besancon,
France; neopterin: IBL International, Hamburg, Germany)
according to the manufacturer’s instructions.
In vitro culture of endothelial progenitor cells
Peripheral blood mononuclear cells (PBMC) were obtained
and cultured as previously described [24, 25]. PBMCs were
isolated by standard Ficoll density gradient centrifugation.
Subsequently, the recovered cells were washed with PBS
and resuspended in HUVEC culture medium containing
RPMI 1640 (Glutamax, GIBCO/Invitrogen, Breda, The
Netherlands), 20 % fetal calf serum (FCS, Integro, Lelystad,
The Netherlands), 100 IU/mL penicillin and 100 μg/mL
streptomycin (Gibco), heparin (20 IE/mL; Leo Pharma,
Breda, The Netherlands) and endothelial cell growth factor
(Reliatech, Wolfenbüttel, Germany) at a concentration of
4*106/mL. 4*106/well were seeded in a 24-well plate, which
was coated before with gelatin 1 %. The cells were cultured
for the next 48 hours at 37 °C, 5 % CO2. Forty-eight hours
after incubation, nonadherent cells were collected and
seeded at a concentration of 1*106/mL on a gelatine-coated
24-well plate. These cells were cultured for another 5 days
to obtain CFU-EC type EPC [24, 25]. Moreover, the
remaining adherent cells were also cultured for another 5
days to obtain ECFC-type EPC [24, 25].
The amounts of clusters were counted before refresh-
ing the media in both the ECFC- and the CFU-EC wells.
A cluster consisted of a colony of multiple (>20) thin
cobblestone-shaped or spindle-shaped cells, tightly clus-
tered together. Clusters were counted manually in at
least two wells per condition by two independent ob-
servers [24, 25]. The calculated intra-assay coefficient of
variation was 21 %.
Statistical analysis
Data are expressed as mean ± SD or median (interquartile
range, IQR). The lower and upper 95 % confidence inter-
val of the mean is given in addition (CI). Statistical signifi-
cance was tested by applying a two-tailed Mann-Whitney
U test. Correlation analysis was performed by means of
the Spearman’s rank correlation. All statistical analyses
were performed with the use of GraphPad Prism software,
version 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).
A p value < 0.05 was considered as statistically significant.
Results
Reduced numbers of cEPC are accompanied by defective
outgrowth of ECFC
cEPC (CD45dim/CD34+/KDR+) were determined directly
ex vivo by flow cytometry. There was a decrease of cEPC
in patients with AAV in remission (AAV-r) and patients
with active AAV (AAV-a) as compared to healthy con-
trols (HC) (given as cells/mL whole blood: AAV-r: 75
(IQR 156, CI 75–220) vs. 504 (IQR 521, CI 139–1508),
p < 0.0001; AAV-a: 52 (IQR 112, CI -32 to 231) vs. 504
(IQR 521, CI 139–1508), p = 0.001, Fig. 1a). No differences
were detected between AAV-r and AAV-a (Fig. 1a). Prolif-
erative capacity of EPC was tested in a culture assay
allowing distinguishing between ECFC and CFU-EC.
The number of ECFC clusters was diminished in quiescent
and active patients as compared to HC (given as clusters/
well: 45 (IQR 125, CI 51–125) vs. 145 (IQR 208, CI
107–242), p < 0.005 and 25 (IQR 141, CI -9 to 196) vs.
145 (IQR 208, CI 107–242), p = 0.07, Fig. 1b). Outgrowth
of CFU-EC, however, was unaltered in patients as
compared to HC (Fig. 1c).
When assessed longitudinally, ECFC outgrowth was
relatively stable in AAV patients and did not normalize
over time (Fig. 2a). However, CFU-EC outgrowth was
less stable (Fig. 2b).
Thus, reduced numbers of cEPC in patients seem to
be accompanied by a specific impairment of ECFC
whereas CFU-EC seem intact.
Angiogenic T cells impact ECFC and CFU-EC
differentiation
T cells have been described to control and support EPC
function [17]. T cells (CD3+) were depleted from PBMC
and cultured. As expected, T cell depletion abolished
ECFC and CFU-EC outgrowth (Fig. 3a). Adding back T
helper cells to T cell-depleted PBMC cultures recovered
ECFC and CFU-EC differentiation confirming the essen-
tial role of T cells for EPC differentiation. Therefore, an-
giogenic T cells (CD3+CD31+, Tang) were further studied
in AAV patients.
We found no difference in relative or absolute num-
bers of Tang when comparing patients in remission and
HC (% of CD3+ T cells: 45 (IQR 24, CI 40–52) vs. 39
(IQR 15, CI 30–46), p = 0.15; Tang/μL whole blood: 398
(IQR 324, CI 364–620) vs. 423 (IQR 298, CI 293–508),
p = 0.74, Fig. 3b). The degree of inflammation (reflected
by sIL-2R or neopterin serum levels), however, corre-
lated negatively with absolute Tang numbers (r = -0.52,
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p = 0.01, n = 23 and r = -0.43, p = 0.04, n = 23) in quies-
cent AAV.
Relapsing disease course is associated with impaired ECFC
outgrowth
Subgroup analyses were performed to assess clinical as-
sociations linked to reduced cEPC or diminished ECFC
outgrowth. Stratification by renal involvement did not
show significant differences between the groups (Fig. 4a).
Likewise, stratifying the patient cohort according to
ANCA-type (PR3/MPO) revealed no significant differ-
ences (Fig. 4b). There was no association between ECFC
and serum creatinine, platelet count, C-reactive protein
or leukocytes (r = -0.29, 0.14, r = -0.04 and r = 0.16, all
p > 0.05). CFU-EC correlated weakly with leukocyte
count (r = -0.35, p = 0.02) but not with serum creatinine,
platelet count or C-reactive protein (r = -0.05, r = 0.18
and r = -0.1, all p > 0.05). cEPC were not significantly as-
sociated with any of the parameters (data not shown).
Furthermore, neither siL2r nor neopterin correlated with
ECFC, CFU-EC, or cEPC (r = -0.27, r = -0.008; r = -0.21,
r = -0.19; r = 0.28, r = 0.26; all p value > 0.05). However, a
relapsing disease course was specifically associated with
impaired ECFC outgrowth but not with CFU-EC out-
growth (Fig. 4c) or cEPC numbers. Moreover, patients
with a relapsing disease course showed an expansion of
Tang whereas patients in long-term stable remission were
not different from HC (% of CD3+ T cells: 59 (IQR 15,
46–63) vs. 39 (IQR 15, CI 30–46), p = 0.006 and 39 (IQR
18, CI 31–47) vs. 39 (IQR 15, CI 30–46), p = 0.89;
Fig. 3c).
Discussion
In this study, we demonstrated that AAV patients have
lower numbers of circulating EPC and we showed that
differentiation into endothelial colony-forming cells (ECFC)
is impaired as compared to HC. Furthermore, we found
that a relapsing disease course in AAV is associated with a
reduced outgrowth of ECFC. Finally, we confirmed that T
cells are essential for EPC differentiation.
Previously, it has been reported that AAV patients
have diminished numbers of circulating EPC [26–28]. In
our study, we confirmed that cEPC were diminished in
AAV. Also, we found that ECFC derived from AAV pa-
tients had an impaired proliferative capacity indicating
that the repair process of damaged endothelium might be
impaired in AAV. Woywodt et al. demonstrated that AAV
patients with quiescent disease have persistently increased
numbers of circulating endothelial cells which may be re-
leased from sites of vascular damage [6]. Based on these
observations, we postulate that even in quiescent disease
there is continuous vascular injury which needs to be
repaired. The overall decrease and reduced differentiation
capacity of EPC populations may cause insufficient vascu-
lar repair. This may contribute to the higher cardiovascu-
lar morbidity and mortality in AAV patients [8].
Because vascular repair is delayed, endothelial damage
may persist resulting in a stimulation of the immune
Fig. 1 Endothelial progenitor cells are diminished and differentially impaired in patients with ANCA-associated vasculitis (AAV). a Circulating endothelial
progenitor cells (EPC) are diminished in patients with active or inactive disease as compared to HC. b, c In patients, proliferative capacity of EPC of the
endothelial cell-forming colonies (ECFC) type is impaired whereas colony-forming units-endothelial cells (CFU-EC) EPC are unaffected. Horizontal
bars represent the mean value. **p value < 0.005. AAV-a AAV patients with active disease, AAV-r patients in remission, HC healthy controls
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system [29]. Continuous vascular injury may then favor
chronic inflammatory immune responses promoting dis-
ease relapses [1, 3, 29].This might explain why patients
with a relapsing disease course had the lowest ECFC
numbers in comparison to patients with a nonrelapsing
disease course or HC.
The results of our study differed from previous studies
[25–27]. In an earlier study by de Groot et al, AAV pa-
tients and HC showed no difference in hematopoietic
stem cell numbers [26]. Furthermore, in this study with
11 active patients, no significant differences between
age-matched HC and AAV-a were found with respect to
ECFC. The differences between this study and our study
might be explained by different techniques used to de-
tect and quantify ECFC. In contrast to our assay, nonad-
herent cells were removed later from the ECFC culture;
furthermore, ECFC were re-seeded within the first week
of culture. The timing of seeding and removal of nonad-
herent cells is critical to the outgrowth of ECFC as has
been described before [30, 31]. Zavada et al. found CFU-
EC to be diminished in patients with AAV as compared
to HC [27]. This is in contrast to the findings in our
study where we found the outgrowth of CFU-EC to be
comparable in HC and in AAV patients. Differences in
the patient cohort probably explain these different find-
ings. Most of the patients in remission were treated with
immunosuppressive drugs (93 %) in the Zavada study,
whereas in our study patients in remission were only eli-
gible if left untreated or receiving a maximum 5 mg of
prednisone. Interestingly, another study by Zavada et al.
demonstrated an association of CFU-EC numbers and
relapse rate [28]. In our study, we found an association
Fig. 2 Longitudinal assessment of EPC differentiation in AAV patients. a ECFC outgrowth was rather stable over time and did not normalize. b CFU-EC
outgrowth was fluctuating over time. CFU-EC colony-forming units-endothelial cells, ECFC endothelial cell-forming colonies, HC healthy controls
Fig. 3 Critical role of T cells in ECFC and CFU-EC differentiation. a Depletion of T cells from ECFC or CFU-EC cultures abolished EPC differentiation.
Adding back T cells restored ECFC and CFU-EC outgrowth indicating the pivotal role of T cells in promoting EPC differentiation. b No significant
difference was found between HC and AAV-r regarding the fraction of circulating CD31+ T cells. c Stratifying patients according to clinical course
reveals that frequent relapsers have an expanded compartment of circulating angiogenic T cells as compared to HC or patients with nonrelapsing
disease course. Horizontal bars represent the mean value, error bars represent the standard of the mean. *p = 0.01, **p = 0.006. AAV-r patients in
remission, CFU-EC colony-forming units-endothelial cells, ECFC endothelial cell-forming colonies, HC healthy controls, PBMC peripheral blood
mononuclear cells
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of ECFC, but not CFU-EC, outgrowth, and tendency to
relapse. Again, this discrepancy might be explained by the
cohort characteristics; the patients enrolled by Zavada et
al. were mostly treated with immunosuppressive agents.
Only recently, a pro-angiogenic role has been described
for T cells [17, 25]. In our study, we could confirm that T
cells are essential for EPC differentiation. Tang, which are
suggested to have pro-angiogenic function, however, have
never been studied in AAV before. We found no differ-
ence comparing Tang numbers between AAV patients and
HC. Subgroup analysis revealed that AAV patients with
relapsing disease course showed an expansion of Tang
whereas ECFC numbers were lower in these patients. Tang
expansion may be an ineffective attempt to compensate
the need for increased EPC function.
In summary, we provide evidence that EPC are im-
paired in AAV. We postulate that insufficient vascular
repair combined with chronic vascular injury may in-
crease the relapse propensity. These factors may contrib-
ute to the higher cardiovascular morbidity as previously
documented in AAV.
Conclusions
We demonstrate that in patients with ANCA-associated
vasculitis (AAV) endothelial progenitor cells are differentially
impaired as compared to healthy controls: endothelial
colony-forming cells (ECFC-type EPC) show defective
differentiation capacity, especially in patients with relapsing
disease course, whereas colony-forming units-endothelial
cells (CFU-EC-type EPC) are intact. Furthermore, we con-
firmed that T cells are essential for ECFC/CFU-EC differ-
entiation and found that these angiogenic T cells are
abnormal in relapsing AAV. In summary, insufficient
vascular repair in AAV may favor a relapsing disease
course. Finally, these factors may explain a higher cardio-
vascular morbidity as has been previously documented in
AAV.
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